Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 4/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1424267 | 0.85 | PIM1 (0.39) | CDK5CDK5R1CYP19A1RETITK | |
| SCHEMBL1483695 | 0.83 | KDM4E (0.40) | CDK5CDK5R1CYP19A1RETPIM1 | |
| SCHEMBL1421155 | 0.80 | CYP19A1 (0.46) | CDK5CDK5R1CYP19A1RETITK | |
| SCHEMBL1422576 | 0.80 | MAPT (0.41) | CDK5CDK5R1CYP19A1ITKPIM1 | |
| SCHEMBL1484245 | 0.79 | KDM4E (0.41) | CDK5CDK5R1CYP19A1RETITK | |
| SCHEMBL1484070 | 0.77 | CYP1A1 (0.45) | CDK5CDK5R1CYP19A1RETPIM1 | |
| SCHEMBL12829963 | 0.77 | CYP2D6 (0.47) | CDK5CDK5R1CYP19A1PIM1 | |
| SCHEMBL1484213 | 0.77 | MAPT (0.37) | CDK5CDK5R1PIM1 | |
| SCHEMBL10550633 | 0.77 | KDM4E (0.51) | CYP19A1 | |
| SCHEMBL1484034 | 0.76 | IDO1 (0.48) | CDK5CDK5R1CYP19A1PIM1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | claimed |
| EP-2296474-A1 | NOVEL SUBSTITUTED INDOLES | Merck Sharp & Dohme Corp. (US) | 2011-03-23 | — | — | EP | claimed |
| WO-2009155024-A1 | NOVEL SUBSTITUTED INDOLES | MERCK & CO., INC. (US) | 2009-12-23 | — | — | WO | claimed |
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | disclosed |
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | disclosed |
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110076230-A1 | Novel Substituted Indoles | APP, BACE1, PSEN1 | CDK5 772/4885CDK5R1 1209/4885CYP19A1 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.